Literature DB >> 16473077

Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics.

Eamonn M M Quigley1, Rodrigo Quera.   

Abstract

Small intestinal bacterial overgrowth is common in intestinal failure. Its occurrence relates to alterations in intestinal anatomy, motility, and gastric acid secretion. Its presence may contribute to symptoms, mucosal injury, and malnutrition. Relationships between bacterial overgrowth and systemic sepsis are of potential importance in the intestinal failure patient because the direct translocation of bacteria across the intestinal epithelium may contribute to systemic sepsis: a phenomenon that has been well established in experimental animal models. The accurate diagnosis of bacterial overgrowth continues to present a number of challenges in clinical practice and especially so among patients with intestinal failure. The management of patients with bacterial overgrowth remains, for the most part, primarily empiric and comprises antibiotic therapy and correction of any associated nutritional deficiencies. Although evidence from experimental animal studies consistently indicates that probiotics exert barrier-enhancing, antibacterial, immune-modulating, and anti-inflammatory effects, which all could be benefits in small intestinal bacterial overgrowth and intestinal failure, their role in human beings remains to be evaluated adequately.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16473077     DOI: 10.1053/j.gastro.2005.11.046

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  79 in total

1.  Lactoferricin B inhibits the phosphorylation of the two-component system response regulators BasR and CreB.

Authors:  Yu-Hsuan Ho; Tzu-Cheng Sung; Chien-Sheng Chen
Journal:  Mol Cell Proteomics       Date:  2011-12-02       Impact factor: 5.911

2.  A review of rifaximin and bacterial overgrowth in poorly responsive celiac disease.

Authors:  Matthew S Chang; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

3.  Prevalence of small intestine bacterial overgrowth diagnosed by quantitative culture of intestinal aspirate in celiac disease.

Authors:  Alberto Rubio-Tapia; Susan H Barton; Jon E Rosenblatt; Joseph A Murray
Journal:  J Clin Gastroenterol       Date:  2009-02       Impact factor: 3.062

Review 4.  Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth.

Authors:  S C Shah; L W Day; M Somsouk; J L Sewell
Journal:  Aliment Pharmacol Ther       Date:  2013-09-04       Impact factor: 8.171

5.  Small intestinal bacterial overgrowth (SIBO) and vitamin K-responsive coagulopathy: a previously unrecorded association.

Authors:  Ricardo Brandt Oliveira; Ana Lourdes Candolo Martinelli; Luiz Ernesto Almeida Troncon; Jorge Elias
Journal:  BMJ Case Rep       Date:  2018-06-06

6.  Mealworm larvae (Tenebrio molitor L.) exuviae as a novel prebiotic material for BALB/c mouse gut microbiota.

Authors:  Gyoo Taik Kwon; Hyun-Gyun Yuk; Su Jung Lee; Yi Hyung Chung; Han Su Jang; Jong-Sang Yoo; Kyung-Hoon Cho; Hyunseok Kong; Daekeun Shin
Journal:  Food Sci Biotechnol       Date:  2019-12-23       Impact factor: 2.391

Review 7.  Diarrhoea due to small bowel diseases.

Authors:  Joseph A Murray; Alberto Rubio-Tapia
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-10       Impact factor: 3.043

8.  Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients.

Authors:  Richard A Schatz; Qing Zhang; Nilesh Lodhia; Jonathan Shuster; Phillip P Toskes; Baharak Moshiree
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

9.  Pediatric small intestine bacterial overgrowth in low-income countries.

Authors:  Jeffrey R Donowitz; William A Petri
Journal:  Trends Mol Med       Date:  2014-11-15       Impact factor: 11.951

10.  Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients.

Authors:  Dae Won Jun; Kyung Tae Kim; Oh Young Lee; Jeong Don Chae; Byoung Kwan Son; Seong Hwan Kim; Yun Ju Jo; Young Sook Park
Journal:  Dig Dis Sci       Date:  2009-06-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.